Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
A phase 1/2 trial of Darovasertib, Binimetinib, Crizotinib in melanoma and uveal melanoma, run by IDEAYA Biosciences, now recruiting.
Overview
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions is a phase 1/2 interventional study registered as NCT03947385 by IDEAYA Biosciences, with 336 participants planned, started 2019-06-28 and due to reach its primary completion in 2027-01-29. Interventions recorded: IDE196, Binimetinib, Crizotinib. Conditions listed: Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- Trial(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma, Melanoma.
- TrialNeoadjuvant Darovasertib in Primary Uveal Melanoma
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
- TrialStudy of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
- TrialIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Shares Darovasertib, IDEAYA Biosciences, Crizotinib, Uveal melanoma.
- TrialAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
Shares Binimetinib, Melanoma.
- TrialA Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Shares IDEAYA Biosciences, Colorectal cancer.
- TrialA Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Shares Binimetinib, Melanoma.
- JournalMelanoma research
Shares Uveal melanoma, Melanoma.